Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Binge-eating disorder
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPD489-345
  • Sponsors Shire

    • Most Recent Events

    • 12 Apr 2017 Study was planned in Italy, Sweden, USA, Germany, Spain but patients were not recruited from Italy and Sweden.
    • 05 Apr 2017 Results assessing safety and efficacy, published in the Journal of Clinical Psychopharmacology
    • 22 Jul 2015 Results were published in the Shire Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top